Accelerated immune reconstitution using LLME treated donor lymphocyte infusions  by Filicko, J.E. et al.
variability. In contrast, a single embryonic stem cell (ESC) line can
be repetitively cryopreserved, thawed, expanded, and differentiated
into various cellular components serving as a renewable and well-
characterized stem cell source. We, therefore, determined whether
ESCs could be used to reconstitute marrow and blood in major
histocompatibility (MHC) mismatched mice. To induce differen-
tiation toward HSC in vitro, ESCs were cultured in methylcellulose
with hematopoietic cytokines, stem cell factor (SCF), interleukin-3
(IL-3), interleukin-6 (IL-6). After 7-10 of culture, H2b ESC-
derived cytokine induced hematopoietic stem cells (c-kit/CD34)
were isolated by ﬂow cytometry and injected either intra bone
marrow (IBM) or intravenously (IV) into lethally irradiate MHC
mismatched H2d recipient mice. From two to twenty weeks after
injection, the peripheral blood demonstrated increasing donor de-
rived H2b positive mononuclear cells that included donor derived
T lymphocytes, B lymphocytes, monocytes and granulocytes with-
out clinical or histologic evidence of graft versus host disease
(GvHD). Mixed lymphocyte culture (MLC) proliferation assays
demonstrated T cell tolerance to both recipient and donor but
intact 3rd party proliferative responses and interferon-
 produc-
tion. Embryonic stem cells may be used as a renewable alternate
marrow donor source that reconstitutes hematopoiesis with intact
immune responsiveness without graft versus host disease despite
crossing MHC barriers.
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ANTI-3RD PARTY VETO CTLS DEPLETED OF HOST REACTIVE CLONES
RETAIN A BROAD TCR REPERTOIRE: A POTENTIAL NEW SOURCE FOR
ADOPTIVE IMMUNE THERAPY IN BONE MARROW TRANSPLANTATION
Aviner, S.1, Bachar-Lustig, E.1, Brouard, S.2, Goren, R.A.1, Guillet,
M.2, Soulillou, J.-P.2, Reisner, Y.1 1. Immunology, Weizmann Institute
of Science, Rehovot, Israel; 2. Institut National de la Sante et de la
Recherche Medicale, Nantes, France
CD8 cytotoxic T lymphocytes (CTLs) are endowed with a
powerful capacity to induce speciﬁc tolerance against their histo-
compatibility antigens (veto). Very recently, we developed a new
approach to deplete CTLs of host-reactive clones by stimulating
the donor T cells against 3rd party stimulators in the absence of
exogenous IL-2. It could be anticipated that this procedure, which
leads to a marked frequency reduction of anti-host clones, should
also be associated with substantial narrowing of the TCR reper-
toire, thereby limiting the use of these veto cells for tolerance
induction. In the present study we used a new technique (TcLand-
scape) which enables qualitative and quantitative analysis of V	
chain usage at the CDR3 length distribution level to compare the
repertoire of anti-3rd party CTLs to that of the original donor.
Mouse and human anti-3rd party CTLs were prepared as previ-
ously described. Mouse splenocytes of Balb/c and FVB were used
as effectors and stimulators, respectively. Human PBMC from
normal donors were stimulated against EBV transformed cell lines,
completely mismatched for HLA class1. cDNA samples obtained
from mouse and human CD8 responder T cells before (day 0)
and after initiation of culture (days 22 and 33 respectively) were
analyzed for V	 repertoire. The analysis showed that in CTLs of
both human and mice, a signiﬁcant ampliﬁcation or reduction was
evident only in particular CDR3 lengths of speciﬁc V	 families.
Thus, mouse anti-3rd party CTLs exhibit marked clonal reductions
in V	3, V	5, V	12, V	13 and V	16. Changes in the latter one
were most dramatic and it is almost oligoclonal. In contrast, only
minor alterations were found in all the other V	 families indicating
a preservation of broad repertoire. Analysis of CDR3 lengths of
anti-3rd party human CTLs showed similar preservation of broad
repertoire along with marked reduction of particular CDR3 length
clones in V	12, V	15 and V	21. These ﬁndings are of particular
relevance to BMT, as it might enable to use anti-3rd party CTLs
not only for enhancement of engraftment, but also for adoptive
transfer of immunity during the early post transplant period. Fur-
thermore, these results raise new possibilities for molecular prob-
ing of the antigens which trigger alloreactivity in mouse and in
man.
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ADOPTIVE TRANSFER OF EX VIVO COSTIMULATED AUTOLOGOUS T-
CELLS AFTER AUTOTRANSPLANTATION FOR MYELOMA (MM)ACCELER-
ATES POST-TRANSPLANT T-CELL RECOVERY
Rapoport, A.P.1, Stadtmauer, E.A.2, Levine, B.L.2, Badros, A.1, Akpek,
G.1, Cotte, J.2, Chrisley, L.1, Veloso, E.1, Westphal, S.1, Zheng, Z.2,
Grandﬁeld, K.2, Ratterree, B.1, Natt, S.1, Hinkle, J.2, Porter, D.2,
Luger, S.2, Ruehle, K.1, George, B.1, Guo, C.1, Mann, D.1, Cross, A.1,
June, C.H.2 1. University of Maryland Greenebaum Cancer Center,
Baltimore, MD; 2. Abramson Family Cancer Center, University of
Pennsylvania, Philadelphia, PA
Ex-vivo co-stimulation of autologous T-cells using anti-CD3/
anti-CD28-conjugated magnetic beads may restore T-cell respon-
siveness toward MM cells. 40 patients (pts) received ex-vivo co-
stimulated autologous T-cells after autotransplantation. The mean
age was 58 (range 43-72), 72% were male, 24% had IgA parapro-
teins, 12% had del 13 or complex karyotypes and the median 	2m
level at diagnosis was 3.32 mg/L (range 1.09-73.7). Lymphocyte
collections were followed by cyclophosphamide (4.5 g/m2) G-CSF
for stem cell mobilization melphalan (200 mg/m2 or 140 mg/m2 for
pts 70). T-cells were cultured for 12 days with anti-CD3/anti-
CD28-immobilized immunomagnetic beads & IL-2 supplementa-
tion (100 units/ml). During a run-in phase, 12 pts received T-cells
post-transplant (day 12) alone; afterwards, 28 pts participated
in a 2  2 randomization in which they received T-cells “early”
(day 12) or “late” (day 100) after transplant also received 2
immunizations with the pneumococcal conjugate vaccine (PCV,
Prevnar®) days 30 90 or 3 immunizations (prior to T-cell
collection, days 30, 90) to test immune responses. 27 pts re-
ceived 1 or more PCV immunizations and there were no grade 3/4
adverse events. Anti-pneumococcal antibody T-cell response assays
are underway for pts who completed the study. 33 pts received a
mean of 8.11  109 costimulated T-cells (range 1.6-11) all infu-
sions were well tolerated. There were no delayed adverse effects
except for grade 1-2 facial/upper body rashes in 6 pts (median 13
days after T-cells) and 1 episode of grade 2 conjunctivitis. At T-cell
harvesting, the mean % of CD3  cells in culture was 94.2% the
mean T-cell doubling level was 5.2. Among the randomized pts, at
day  42 post-transplant (30 days after T-cell infusion for the
“early” groups), the mean CD4/CD3 count was 679/l (95% CI,
347-1012) for the “early” T-cell recipients vs 278/l (95% CI,
59-497) for the “late” T-cell recipients (T-cells not yet infused)
[P  0.03]. The mean CD8/CD3 counts were 1826/l (95% CI,
1275-2376) 1105/l (95% CI, 404-1806) for the “early” and “late”
T-cell recipient respectively at day 42 [P  0.07]. 32 pts were
evaluable for clinical responses (8 are too early). There were 6 CRs,
15 VGPRs (90% reduction in paraprotein levels), 10 PRs (50-
90% reductions), 1 pt had no response. Post-transplant infusions of
ex-vivo expanded autologous T-cells are feasible and well-tolerated
may be associated with accelerated T-cell recovery.
44
ACCELERATED IMMUNE RECONSTITUTION USING LLME TREATED DO-
NOR LYMPHOCYTE INFUSIONS
Filicko, J.E.1, Grosso, D.1, Flomenberg, P.1, Friedman, T.1, Brunner,
J.1, Dessain, S.1, Drobyski, W.2, Ferber, A.1, Kakhniashvili, I.1,
Keever-Taylor, C.2, Mookerjee, B.1, Wagner, J.L.1, Williams, A.1,
Korngold, R.1, Flomenberg, N.1 1. Thomas Jefferson University, Phil-
adelphia, PA; 2. Medical College of Wisconsin, Milwaukee, WI
Delayed immune reconstitution is a major cause of morbidity and
mortality after T-cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 9 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after its polymerization by dipeptidyl pep-
tidase, leading to selective depletion of cells with cytotoxic effector
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granules containing perforin. Products treated with LLME dem-
onstrated a median depletion of 92% of CD56 cells, 67 % of
CD8 cells, but only 37% of CD4 cells. Patients initially re-
ceived 10e4 (haploidentical donor, n  3), 10e5 (HLA identical
unrelated donor, n  1), 10e6 (HLA identical sibling donor, n 
4), or 10e7 (HLA identical sibling donor, n  1) CD3 cells/kg in
cohorts of 3, and were eligible for additional infusions at a one log
higher dose after 28 days if there was no evidence of GVHD or the
CD4 count was less than the target of 200 cells/l. The initial dose
was escalated by one log in subsequent cohorts if no complications
were observed in the previous cohort. All patients had pre-DLI
CD4 counts of 5.0 cells/l, and received 1 to 3 infusions post
PCT. Since ATG was used during PCT cytoablation, the ﬁrst DLI
infusions were administered after ATG levels were 2 mcg/ml.
After DLI #1, 4 of 5 matched sibling recipients and 1 of 1 unrelated
donor recipients demonstrated increased CD4 counts with a
median increase of 68 donor derived CD4 cells/l (range 57-
460). Three of these patients achieved a CD4 count above 200
after 1-3 total infusions. In contrast, none of the haploidentical
recipients (receiving the smallest doses) had an increase in their
CD4 counts. Two patients developed mild GVHD (1 haploiden-
tical Grade II, 1 matched sibling Grade I). In recovering patients,
spectratype analysis of CD4 cells comparing donor lymphocytes
before LLME treatment with lymphocytes recovered from the
patients post DLI demonstrated that 94% of the resolvable Vß
families were equally complex. Perforin positive cells, as well as
adenovirus and CMV speciﬁc lymphocytes, also recovered post
PCT in these patients. These preliminary results suggest that
LLME treated DLI can accelerate CD4 reconstitution without
causing severe GVHD.
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NON-GVHD-INDUCING CD62L- MEMORY T CELLS PROMOTE NEW T
CELL REGENERATION FROM HEMATOPOIETIC STEM CELLS
Chen, B.J., Cui, X., Son, J., Chao, N.J. Duke University Medical
Center, Durham, NC
We previously demonstrated that allogeneic CD62L- memory T
cells from unprimed donor mice are unable to induce graft-versus-
host disease (GVHD) in allogeneic host (Blood. Prepublished
October 9, 2003; DOI 10.1182/blood-2003-08-2987). In this pub-
lished study, we also demonstrated that in contrast to bulk T cells
and CD62L T cells, CD62L- T cells contribute to post-trans-
plant T cell reconstitution not only by peripheral expansion but
also by promoting new T cells from T cell-depleted bone marrow.
To investigate whether the new T cells were indeed generated
from hematopoietic stem cells, we transplanted 1x106 CD62L-
splenic T cells from C57BL/6 mice (H2b, CD45.2) along with
5000 puriﬁed c-KitThy1.1lowLin-/lowSca-1 hematopoietic stem
cells from congenic C57BL/6 mice (H2b, CD45.1) into lethally
irradiated (8.5 Gy) BALB/c mice (H2d, CD45.2). Phenotypic T
cell recovery was then followed weekly in the ﬁrst 8 weeks and then
once every other week until day 100 after transplantation. In this
model, the origin of different T cells can be distinguished by ﬂow
cytometry (donor CD62L- T cell-derived: H2DbCD45.2, do-
nor stem cell-derived: H2DbCD45.1, host-type: H2Db-
CD45.2-). Stem cell-derived T cells could not be detected in
peripheral blood in any recipient during the ﬁrst month following
transplantation. By day35, stem cell-derived CD4 and CD8T
cells became detectable in mice receiving only puriﬁed stem cells.
However, the addition of CD62L- cells into the graft dramatically
increased stem cell-derived CD4 and CD8 T cell numbers in
peripheral blood (Table). This effect lasted through day 49. By
day 56, stem cell-derived T cell numbers became equivalent in
both groups. These data demonstrate that CD62L- T cells can
accelerate new T cell development from hematopoietic stem cells
presumably through thymopoiesis. Mature T cells could not me-
diate this effect in syngeneic hosts, suggesting that this is an
allogeneic effect. CD62L- T cells may be mediating the effect
through enhancing the level or speed of stem cell engraftment
since CD62L- T cells also imporved total white cell recovery. In
conclusion, our data suggest that CD62L- memory T cells repre-
sent a unique population of T cells which do not cause GVHD but
are capable of promoting new donor T cell generation from he-
matopoietic stem cells after allogeneic hematopoietic cell trans-
plantation.
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T CELL DEPLETED HOSTS ARE UNIQUELY SUSCEPTIBLE TO TOLER-
ANCE INDUCED BY NON-PROFESSIONAL APCS AND MEDIATED BY
IL-10 PRODUCING CD8 T CELLS
Fry, T.J.1, Melchionda, F.2, Mackall, C.L.1 1. Pediatric Oncology
Branch, NCI,NIH, Bethesda, MD; 2. S. Orsola Hospital, University of
Bologna, Pediatric Oncology-Hematology & Cell Therapy Unit, Bologna,
Italy
Background: Emerging evidence indicates that the immunobi-
ology of T cell depleted (TCD) hosts differs from normal hosts.
We observed increased susceptibility to tolerance after T cell
depletion and hypothesize that mechanisms at work in this model
are relevant for induction of immune responses following BMT.
Methods: Thymectomized, TCD C57BL/6 female mice reconsti-
tuted with naive T cells were immunized with male dendritic cells
(DC) or male splenocytes. T cell responses to HY were measured
using skin graft rejection, tetramer and ELISPOT. Male skin graft
rejection correlated with expansion of HY-reactive CD8 cells and
IFN
 production in response to HY by CD4 and CD8 cells.
Results: TCD recipients of male DC generate HY speciﬁc immu-
nity but not recipients of male splenocytes. TCD, male splenocyte
immunized animals are tolerant to HY since attempts to sensitize
with male DC were unsuccessful. Splenic B cells were necessary
and sufﬁcient to induce this tolerance. B cell induced tolerance to
HY in TCD hosts could not be reversed by restoring normal T cell
number through placement of a thymic graft or adoptive transfer
of new naive T cells indicating immune suppression. CD8 T cells,
but not CD4 T cells, were sufﬁcient to mediate suppressive toler-
ance to HY. T cells from IL10-/- mice could not mediate tolerance
whereas TGF	 neutralization had no effect. Thus, residual CD8
cells induce suppressive tolerance to HY after encounter with male
B cells. Since TCD hosts have increased IL7, we hypothesized that
IL7 might play a role in T cell depletion-induced tolerance. In-
deed, neutralization of IL7 and IL7R at the time of T-B cell
encounter prevented tolerance in the majority of animals. Con-
clusions: Although IL7 induced homeostatic expansion in TCD
hosts is now widely appreciated as a mechanism which enhances
immune responses to low afﬁnity and self antigens, the factors
which prevent autoimmunity in this setting remain unclear. These
results give rise to a model wherein increased IL7 in TCD hosts
prevents autoimmunity by inducing CD8/IL10 mediated suppres-
sive tolerance to antigen presented on non-professional APCs.
Therefore TCD hosts are uniquely susceptible to tolerance induc-
tion during T cell regeneration due to stringent APC require-
ments. While this may prevent autoimmunity during T cell regen-
eration, it may also limit the success of immune based therapies
directed toward infectious and neoplastic antigens in clinical situ-
ations involving T cell depletion.
Table. Allogeneic CD62L T Cells Promote New T-cell
Regeneration from Hematopoietic Stem Cells
Groups
CD62L
T-cell–
derived
(cells/L
Blood)
Stem
cell–
derived
(cells/L
Blood)
CD4 CD8 CD4 CD8
Stem cell
only 3  1 1  1 104  84 18  17
stem cell 
CD62L
T cell 32  18* 50  8* 390  141* 97  24*
*P .01, compared with stem cell only. Data were from day 35.
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